Treatment strategies aiming at remission in early rheumatoid arthritis patients: Starting with methotrexate monotherapy is cost-effective

Rheumatology

Volumn 50, Issue 7, 2011, Pages 1320-1330

  Schipper, Lydia G ^a   Kievit, Wietske ^a   den Broeder, Alfons A ^b   van der Laar, Mart A ^c   Adang, Eddy M M ^a   Fransen, Jaap ^a   van Riel, Piet L C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b Sint Maartenskliniek Nijmegen ^*  (Netherlands)

^c UNIVERSITY OF TWENTE   (Netherlands)

Author keywords

Combination drug therapy; Cost effectiveness analysis; Remission induction; Rheumatoid arthritis; Therapeutic use

Indexed keywords

ADALIMUMAB; ETANERCEPT; LEFLUNOMIDE; METHOTREXATE; RITUXIMAB;

ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; HEALTH CARE COST; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; QUALITY OF LIFE; REMISSION; RHEUMATOID ARTHRITIS;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; COST OF ILLNESS; COST-BENEFIT ANALYSIS; DRUG COSTS; DRUG THERAPY, COMBINATION; EARLY DIAGNOSIS; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOXAZOLES; MALE; MARKOV CHAINS; METHOTREXATE; MIDDLE AGED; NETHERLANDS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79959436349     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/ker084     Document Type: Article

References (61)

1. Breedveld FC. Current and future management approaches for rheumatoid arthritis. Arthritis Res 2002; 4(Suppl. 2):S16-21.
2. Smolen JS, Aletaha D, Machold KP. Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005;19:163-77.
3. Emery P, Breedveld FC, Hall S et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 2008;372: 375-82.
4. van Tuyl LH, Lems WF, Voskuyl AE et al. Tight control and intensified COBRA combination therapy in early rheumatoid arthritis: 90% remission in a pilot trial. Ann Rheum Dis 2008;67:1574-7.
5. Yelin E, Wanke LA. An assessment of the annual and long-term direct costs of rheumatoid arthritis: the impact of poor function and functional decline. Arthritis Rheum 1999;42:1209-18.
6. Combe B. Early rheumatoid arthritis: strategies for prevention and management. Best Pract Res Clin Rheumatol 2007;21:27-42.
7. Choy EH, Smith C, Dore CJ, Scott DL. A meta-analysis of the efficacy and toxicity of combining diseasemodifying anti-rheumatic drugs in rheumatoid arthritis based on patient withdrawal. Rheumatology 2005;44: 1414-21.
8. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
9. Bathon JM, Martin RW, Fleischmann RM et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000;343: 1586-93.
10. Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum 2003;48:2750-62.
11. Kremer JM, Genovese MC, Cannon GW et al. Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002;137:726-33.
12. Strand V, Cohen S, Schiff M et al. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med 1999;159: 2542-50.
13. Klareskog L, van der Heijde D, de Jager JP et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 2004;363:675-81.
14. van der Heijde D, Klareskog L, Rodriguez-Valverde V et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. Arthritis Rheum 2006;54:1063-74.
15. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
16. Van den Hout WB, Goekoop-Ruiterman YP, Allaart CF et al. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2009;61:291-9.
17. Kievit W, Fransen J, Oerlemans AJ et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomized controlled trials and clinical practice. Ann Rheum Dis 2007;66:1473-8.
18. Zink A, Strangfeld A, Schneider M et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. Arthritis Rheum 2006;54:3399-407.
19. Hunink MG, Glasziou PP, Siegel JE et al. Decision making in health and medicine: integrating evidence and values. 2nd edition. Cambridge: Cambridge University Press, 2001.
20. Newsome G. Guidelines for the management of rheumatoid arthritis: 2002 update. J Am Acad Nurse Pract 2002; 14:432-7.
21. O'Dell JR. Therapeutic strategies for rheumatoid arthritis. N Engl J Med 2004;350:2591-602.
22. Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997;36:1082-8.
23. Haagsma CJ, Russel FG, Vree TB et al. Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: pharmacokinetic analysis and relationship to clinical response. Br J Clin Pharmacol 1996;42:195-200.
24. Breedveld FC, Dayer JM. Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000;59:841-9.
25. Osiri M, Shea B, Robinson V et al. Leflunomide for treating rheumatoid arthritis. Cochrane Database Syst Rev 2003;(1): CD002047.
26. Welsing PM, Severens JL, Hartman M et al. The initial validation of a Markov model for the economic evaluation of (new) treatments for rheumatoid arthritis. Pharmacoeconomics 2006;24:1011-20.
27. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK et al. Probability of continued low disease activity in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis 2008;67:266-9.
28. Welsing PM, van Riel PL. The Nijmegen inception cohort of early rheumatoid arthritis. J Rheumatol 2004; 69(Suppl.1):14-21.
29. Kievit W, Adang EM, Fransen J et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. Ann Rheum Dis 2008; 67:1229-34.
30. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-24.
31. Dutch Health Insurance Executive Board. Pharmacotherapeutic compass. Diemen, The Netherlands, 2006.
32. Wick MC, Ernestam S, Lindblad S et al. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. Scand J Rheumatol 2005; 34:353-8.
33. Katchamart W, Johnson S, Lin HJ et al. Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res 2010;62:1128-43.
34. Hartman M, Van Ede A, Severens JL et al. Economic evaluation of folate supplementation during methotrexate treatment in rheumatoid arthritis. J Rheumatol 2004;31: 902-8.
35. Edwards JC, Szczepanski L, Szechinski J et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-81.
36. Briggs A, Fenn P. Trying to do better than average: a commentary on 'statistical inference for costeffectiveness ratios'. Health Econ 1997;6:491-5.
37. Drummond MF, O'Brien B, Stoddart GL, Torrance GW. Methods for the economic evaluation of health care programmes. 2nd edition. Oxford: Oxford University Press, 1997.
38. Rutten-van Molken M, Buscback van J, Rutten F. Van kosten tot effecten: een handleiding voor evaluatiestudies in de gezondheidszorg [Costs and effectiveness: a guideline for studies of evaluation in health care]. Amsterdam, The Netherlands: Elsevier gezondheidszorg, 2000.
39. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ 1995;14:171-89.
40. Chen YF, Jobanputra P, Barton P et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. Health Technol Assess 2006;10:iii-xiii.
41. Finckh A, Bansback N, Liang MH. Cost-effectiveness of biologics in early rheumatoid arthritis. Ann Intern Med 2010;152:333-4.
42. Quinn MA, Conaghan PG, O'Connor PJ et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005;52:27-35.
43. Emery P, Genovese MC, van Vollenhoven R et al. Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol 2009;36:1429-41; erratum in J Rheumatol 2010;37:2198.
44. Verstappen SM, Jacobs JW, Hyrich KL. Effect of anti-tumor necrosis factor on work disability. J Rheumatol 2007;34:2126-8.
45. van Vollenhoven RF, Ernestam S, Geborek P et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009;374: 459-66.
46. van Tuyl LH, Boers M, Lems WF et al. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. Ann Rheum Dis 2010;69:807-12.
47. Kobelt G, Eberhardt K, Jonsson L, Jonsson B. Economic consequences of the progression of rheumatoid arthritis in Sweden. Arthritis Rheum 1999;42:347-56.
48. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. Am J Med 2002;113:400-8.
49. Lajas C, Abasolo L, Bellajdel B et al. Costs and predictors of costs in rheumatoid arthritis: A prevalence-based study. Arthritis Rheum Arthritis Care Res 2003;49:64-70.
50. Barton P, Jobanputra P, Wilson J et al. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis - introduction. Health Technol Assess 2004;8:iii, 1-91.
51. Clark W, Jobanputra P, Barton P, Burls A. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. Health Technol Assess 2004;8:iii-x.
52. Drossaers-Bakker KW, De Buck M, Van Zeben D et al. Long-term course and outcome of functional capacity in rheumatoid arthritis - the effect of disease activity and radiologic damage over time. Arthritis Rheum 1999;42: 1854-60.
53. Welsing PM, van Gestel AM, Swinkels HL et al. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum 2001;44:2009-17.
54. Krishnan E, Sokka T, Hakkinen A et al. Normative values for the health assessment questionnaire disability index: benchmarking disability in the general population. Arthritis Rheum 2004;50:953-60.
55. van Gestel AM, Prevoo ML, van't Hof MA et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
56. Gabriel SE, Drummond M, Maetzel A et al. OMERACT 6 economics working group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J Rheumatol 2003;30:886-90.
57. Miettinen OS. The need for randomization in the study of intended effects. Stat Med 1983;2:267-71.
58. van der Kooij SM, Allaart CF, Dijkmans BA, Breedveld FC. Innovative treatment strategies for patients with rheumatoid arthritis. Curr Opin Rheumatol 2008;20: 287-94.
59. Combe B, Landewe R, Lukas C et al. EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2007;66:34-45.
60. Keystone EC, Kavanaugh AF, Sharp JT et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004;50:1400-11.
61. van der Kooij SM, Le Cessie S, Goekoop-Ruiterman YP et al. Clinical and radiological efficacy of initial versus delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis 2008;8:iii-iv, ix-x, 1-105.